Timothy J. Slattery

Phone202.434.7343

Peer Rating
N/R
 N/R

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials
 

Practice Areas

  • Antitrust
     
    Contact InfoTelephone: 202.434.7343
    Fax: 202-434-7400
    Internet: Each Attorney's Internet Address takes the following form: first initial, last name @mintz.com (e.g., rmintz@mintz.com)

    http://www.mintz.com/professionals/detail/name/timothy-j-slattery
     
    University College of William & Mary (B.A., Economics; B.B.A., Finance, 2006)
     
    Law SchoolWilliam and Mary Law School, J.D., 2009
     
    AdmittedVirginia; (not admitted in DC); District of Columbia; (not admitted in DC). (Not admitted in District of Columbia)
     
    Biography

    Tim* has experience on a wide range of antitrust, health care, telecommunication, and litigation matters in federal court and government investigations before the Department of Justice and Federal Trade Commission. He has assisted clients in responding to agency demands and helped guide clients through the Hart-Scott-Rodino merger review process. Tim has also advised clients on the potential antitrust implications of proposed joint ventures. In addition to his antitrust practice, Tim is active in the firm's pro bono program, including working with a pro bono client to draft an amicus brief for the Supreme Court.

    Prior to joining the firm, Tim served for four years as a staff attorney in the Health Care Division of the Federal Trade Commission's Bureau of Competition. During his time with the FTC, Tim conducted and defended numerous investigational hearings and depositions of fact and expert witnesses, participated in pharmaceutical reverse payment litigation in federal district court, and was selected to lead a seminar presented to attorneys and economists on investigational techniques. Tim also conducted investigations into physician joint ventures and reviewed physicians' clinical integration programs with an eye toward antitrust enforcement. Tim's work with the FTC also involved reviewing and analyzing pharmaceutical patent settlement filings under the Medicare Modernization Act (MMA), in addition to then creating a comprehensive database in which to house the filings.

    While in law school, Tim served as the Senior Notes Editor for the William & Mary Bill of Rights Journal. His student note was published in the journal in Spring 2009.

    Newsroom
    •Mintz Levin Files Amicus Brief in Pivotal First Amendment Case, Elonis v. United States, (10.07.2014)

    Awards & Recognitions
    •Phi Beta Kappa
    •Sharpe Community Scholar, College of William & Mary
    •Alumni Prize in Business, College of William & Mary

    Publications
    •Co-author, What Pom Wonderful v. FTC Means for Class Actions, Law360 (02.19.2015)
    •Co-author, FTC Tastes Sweet Victory in POM Wonderful Deceptive Advertising Appeal, Antitrust Alert (02.17.2015)
    •Co-author, DOJ Releases Electrifying New Guidance on Standard-Essential Patent Policy, Antitrust Alert (02.11.2015)
    •Co-author, An Early Test of Antitrust Ramifications of FDA's REMS, Law360 (01.27.2015)
    •Co-author, Medtronic Deal Highlights FTC Focus On Future Competition, Law360 (01.22.2015)
    •Co-author, District Court Permits Section 2 Claim to Proceed Against Pharmaceutical Manufacturer for Denying Generic Rival Access to Branded Drug Samples, Antitrust Alert (01.09.2015)
    •Co-author, Medtronic and Covidien's Blockbuster Medical Products Merger Clears FTC Antitrust Review with Divestiture, Antitrust Advisory (12.05.2014)
    •Author, Milk Processors Soured After Rare Monopsony Ruling, Law360 (06.23.2014)
    •Author, Milk Processors Soured After Federal District Court Rules They Must Face Monopsonization Claims at Trial, Antitrust Alert (06.20.2014)
    •Co-author, Antitrust Hospital Merger Policy Gets a Judicial Boost - Sixth Circuit Upholds FTC Decision Challenging Hospital Merger, Antitrust Alert (04.23.2014)
    •Co-author, NCAA Player Antitrust Class Action Advances to Final Round, Law360 (04.22.2014)
    •Co-author, Busting Brackets: District Court Rejects NCAA's Summary Judgment Motion and Allows Student-Athletes' Suit for Publicity Compensation to March to Trial, Antitrust Alert (04.18.2014)
    •Co-author, FTC Check-Up on Health Care Trends Reveals New Competitive Wrinkles-Highlights from the FTC Workshop “Examining Health Care Competition, Health Lawyers Weekly (04.11.2014)
    •Co-author, FTC Check-Up on Health Care Trends Reveals New Competitive Wrinkles, Antitrust Advisory (03.27.2014)
    •Author, Note, The Dormant Commerce Clause: Adopting a New Standard and a Return to Principle, 17 WM. & MARY BILL RTS. J. 1243 (2009)

     
    ISLN922634971
     

    Documents by this lawyer on Martindale.com

    Subscribe to this feed

    FTC Looks to Accelerate Oncology Drug Growth by Requiring Novartis to Divest Two Protein Inhibitors in Its Clinical Development Pipeline
    Timothy J. Slattery,Bruce D. Sokler, March 27, 2015
    The Federal Trade Commission (“FTC”) on Monday completed its review of Novartis AG’s (“Novartis”) proposed $16 billion acquisition of GlaxoSmithKline’s (“GSK”) oncology drug portfolio with an announced consent decree that requires limited divestitures...

    District Court Permits Section 2 Claim to Proceed Against Pharmaceutical Manufacturer for Denying Generic Rival Access to Branded Drug Samples
    Dionne C. Lomax,Timothy J. Slattery, March 10, 2015
    On December 22, 2014, a federal district court in New Jersey found that Mylan Pharmaceuticals, Inc. (“Mylan”) alleged facts sufficient to plead an antitrust claim under Section 2 of the Sherman Act against defendant, Celgene Corporation (“Celgene”), for denying a generic...

    Medtronic and Covidien’s Blockbuster Medical Products Merger Clears FTC Antitrust Review with Divestiture
    Dionne C. Lomax,Timothy J. Slattery, February 18, 2015
    The Federal Trade Commission (“FTC”) last week green-lighted Medtronic, Inc.’s (“Medtronic”) $42.9 billion acquisition of Covidien plc (“Covidien”) after Medtronic agreed to a settlement that requires Medtronic to divest its drug-coated balloon catheter...

    Profile Visibility
    #3,227 in weekly profile views out of 58,936 lawyers in Washington, District of Columbia
    #119,626 in weekly profile views out of 1,691,864 total lawyers Overall

    Office Information

    Timothy J. Slattery

    701 Pennsylvania Avenue, N.W.
    WashingtonDC 20004-2608




    Loading...
     

    Professional Networking for Legal Professionals Only

    Quickly and easily expand your professional
    network - join the premier global network for legal professionals only. It's powered by the
    Martindale-Hubbell database - over 1,000,000 lawyers strong.
    Join Now